Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A 28-amino-acid neuropeptide naturally produced throughout the body, with particularly high concentrations in the gut, lungs, and nervous system. VIP has potent anti-inflammatory, vasodilatory, and immunomodulatory properties. It gained significant attention during COVID-19 as aviptadil (synthetic VIP) was studied for acute respiratory distress. In integrative medicine, it is widely used for chronic inflammatory response syndrome (CIRS) and mold illness protocols.
A synthetic 15-amino acid peptide derived from a protective protein found in human gastric juice. One of the most widely researched peptides for tissue repair and recovery.
Binds to VPAC1 and VPAC2 receptors, activating cAMP-dependent pathways that suppress pro-inflammatory cytokines (TNF-α, IL-6, IL-12) while promoting anti-inflammatory cytokines (IL-10). Also acts as a potent vasodilator, bronchodilator, and neuroprotective agent. In the lungs, VIP protects alveolar type II cells from inflammatory damage.
BPC-157 promotes angiogenesis (new blood vessel formation), upregulates growth factor expression, and modulates nitric oxide synthesis. It appears to accelerate healing of tendons, ligaments, muscles, and the GI tract through multiple pathways including the FAK-paxillin pathway.
- Chronic inflammatory response syndrome (CIRS)
- Mold illness treatment (Shoemaker protocol)
- Pulmonary hypertension
- Neuroinflammation
- GI motility disorders
- Tendon and ligament repair
- Gut healing and GI protection
- Muscle injury recovery
- Joint health
- Post-surgical recovery
- Hypotension (due to vasodilation)
- Diarrhea at higher doses
- Nasal irritation with intranasal use
- Flushing and headache
- Limited standardized clinical data for CIRS indication
- Limited human clinical trial data
- Most research is animal-based
- Potential interactions with blood pressure medications
- Injection site reactions
- Long-term safety profile unknown
Aviptadil (synthetic VIP) has been studied in clinical trials for ARDS and pulmonary hypertension. Not FDA-approved for any indication. Used off-label by integrative medicine practitioners for CIRS. The Shoemaker CIRS protocol includes intranasal VIP as a final step, though this use is not FDA-sanctioned.
On April 15, 2026, the FDA announced BPC-157 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. It is now scheduled for formal PCAC (Pharmacy Compounding Advisory Committee) review on July 23, 2026, to determine whether it should be added to the 503A bulk drug substances list. Removal from Category 2 does not authorize compounding — pharmacies should exercise caution until PCAC issues its recommendation. Previously reclassified to Category 1 in February 2026, a step that is now superseded by this more formal process.
PCAC: July 23, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.